Stroke prevention in atrial fibrillation: another step sideways

The Lancet

Volumn 371, Issue 9609, 2008, Pages 278-280

  Go, Alan S ^a   Singer, Daniel E ^b  

^a KAISER PERMANENTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; IDRAPARINUX; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; OLIGOSACCHARIDES; STROKE; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 44349094881     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60143-9     Document Type: Note

References (12)

1. The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371 (2008) 315-321
2. Hart R., Pearce L., and Aguilar M. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007) 857-867
3. Go A., Hylek E., Henault L., Selby J., and Singer D. Prevalence of diagnosed atrial fibrillation: national implications for management and stroke prevention: the ATRIA study. Circulation 100 suppl (1999) 1-397
4. Hylek E., Go A., Chang Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349 (2003) 1019-1026
5. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293 (2005) 690-698
6. The Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362 (2003) 1691-1698
7. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006) 1903-1912
8. Boulanger L., Kim J., Friedman M., Hauch O., Foster T., and Menzin J. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract 60 (2006) 258-264
9. Lip G. Preventing stroke in atrial fibrillation: the SPORTIF programme. Pathophysiol Haemost Thromb 34 suppl 1 (2005) 25-30
10. Snapinn S., and Jiang Q. Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials. Stat Med 27 (2008) 382-391
11. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl 3 (2004) 204-233
12. Singer D., Albers G., Dalen J., Go A., Halperin J., and Manning W. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl 3 (2004) 429-456